Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00393-6/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=covidalerts&utm_medium=email&_hsmi=271757280&_hsenc=p2ANqtz-_vfndUd6j-51UnfLag_wW2TmloKJGEtmQZHYqTw7bhpfdhT7xa4s9ZtLxXOgfWXR6qbzDCJAfjlc-65loG09LJwnwJFA&utm_content=271743104&utm_source=hs_email